Adamax
An enhanced derivative of Semax with N-terminal acetylation and C-terminal adamantane modification, engineered for superior blood-brain barrier penetration, BDNF upregulation, and sustained nootropic effects.
What is Adamax?
Adamax is a synthetic nootropic peptide and enhanced derivative of Semax, modified with N-terminal acetylation and a C-terminal adamantane group. These structural modifications improve stability against enzymatic degradation and enhance blood-brain barrier penetration compared to the parent compound. Like Semax, Adamax is derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), but its modifications are designed to produce more potent and sustained nootropic effects. It is primarily researched for cognitive enhancement, neuroprotection, and neuroplasticity via BDNF and TrkB receptor modulation. Adamax has no PubMed-indexed publications under its own name — its theoretical basis rests entirely on Semax research plus the known pharmacological properties of its structural modifications.
What Adamax Is Investigated For
Adamax is discussed for cognitive enhancement, BDNF-mediated neuroplasticity, and neuroprotection — use cases inherited almost entirely from its parent compound Semax rather than from any independent research on Adamax itself. The most fundamental caveat is that Adamax has zero PubMed-indexed publications under its own name: every proposed benefit is extrapolated from Semax's moderate Russian clinical evidence plus general pharmacology of the adamantane modification used in drugs like amantadine and memantine. The claimed advantage — enhanced blood-brain barrier penetration and longer-lasting nootropic effects — is mechanistically defensible but has never been measured for this specific compound. Unlike Semax, which holds Russian medicine registration for stroke and cognitive indications, Adamax has no regulatory status anywhere and exists only in research-chemical channels where structural identity and purity cannot be independently verified. The honest framing is a theoretical 'Semax-plus' with no direct evidence base of its own.
History & Discovery
Adamax sits within the broader Russian-origin lineage of ACTH(4-10)-derived nootropic peptides anchored by Semax, a peptide developed at the M.V. Lomonosov Moscow State University and the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and 1990s. The base sequence (Met-Glu-His-Phe-Pro-Gly-Pro) corresponds to a fragment of adrenocorticotropic hormone with melanocortin-derived neuroactive properties. Over time, derivative chemistries emerged aimed at extending half-life and improving central exposure: N-terminal acetylation to block aminopeptidase degradation, C-terminal amidation in the case of NA-Semax-Amidate, and — for Adamax — replacement of the C-terminal amide with an adamantane cage moiety modeled on the lipophilic-stabilizer chemistry of CNS drugs like amantadine and memantine. Unlike Semax itself, Adamax has essentially no independent published research footprint under its own name. It exists in the gray-market peptide ecosystem as a 'Semax-plus' research compound, with claims that the adamantane modification confers superior blood-brain barrier penetration and longer-lasting BDNF/TrkB modulation. Those claims are mechanistically defensible in principle — the pharmacokinetic logic of adamantane derivatives is real — but they are not backed by indexed publications validating the specific compound, and the entire 'enhanced Semax' positioning rests on extrapolation from the parent molecule rather than direct experimental characterization.
How It Works
Adamax is designed to get into the brain more effectively than its parent compound Semax. Once there, it's proposed to boost BDNF — a protein that strengthens connections between brain cells, supporting learning, memory, and cognitive function. The adamantane group acts like a molecular passport, helping the peptide cross the blood-brain barrier more efficiently.
Adamax is a synthetic derivative of the ACTH(4-10) analog Semax, with N-terminal acetylation (protecting against aminopeptidase degradation) and C-terminal adamantane conjugation (a lipophilic cage hydrocarbon that enhances membrane permeability and blood-brain barrier penetration). The proposed mechanism mirrors Semax: upregulation of BDNF expression and TrkB receptor sensitivity in hippocampal neurons, modulation of monoamine neurotransmitters (dopamine, norepinephrine, serotonin), and neuroprotective effects via antioxidant and anti-inflammatory pathways. The adamantane moiety is pharmacologically significant — adamantane derivatives include established CNS drugs amantadine (dopaminergic) and memantine (NMDA antagonist), suggesting the modification may contribute additional neuroactive properties beyond improved pharmacokinetics. However, none of these proposed mechanisms have been validated for Adamax specifically.
Evidence Snapshot
Human Clinical Evidence
None. No human studies exist for Adamax. The parent compound Semax has moderate clinical evidence from Russian studies for stroke recovery, cognitive enhancement, and ADHD.
Animal / Preclinical
None specific to Adamax. Semax has extensive preclinical data demonstrating BDNF upregulation, neuroprotection, and cognitive enhancement in rodent models. NA-Semax-Amidate (a related derivative) also lacks independent published data.
Mechanistic Rationale
Theoretical. The rationale combines validated Semax pharmacology with known properties of adamantane modifications (enhanced lipophilicity, BBB penetration, metabolic stability). Sound in principle but unvalidated for this specific compound.
Research Gaps & Open Questions
What the current literature has not yet settled about Adamax:
- 01Any peptide-specific clinical or preclinical study — Adamax has zero PubMed-indexed publications under its own name, which is the most fundamental research gap a peptide can have.
- 02Verification of the claimed enhanced blood-brain barrier penetration — the pharmacokinetic rationale for adamantane modification is sound in principle but has not been measured for this specific compound.
- 03Independent confirmation of structural identity and purity in research-chemical supply — adamantane conjugation chemistry is non-trivial and gray-market product identity has not been independently audited.
- 04Comparative pharmacology versus Semax and NA-Semax-Amidate — no head-to-head data establishes whether Adamax actually offers any advantage over its better-studied parent and sibling compounds.
- 05Long-term safety of adamantane-conjugated peptides administered chronically — the established adamantane CNS drugs are small molecules, not peptide conjugates, so safety extrapolation is limited.
- 06Human pharmacokinetics across routes — intranasal, subcutaneous, and any other administration route lacks direct measurement of plasma or CSF exposure.
Forms & Administration
Adamax is available as a research compound, typically as a nasal spray or lyophilized powder. Intranasal administration is the most common route for nootropic peptides in this class. It is not FDA-approved and not available through legitimate medical channels.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no clinically established Adamax dose because the compound has not been studied in clinical trials. Forum and vendor protocols typically describe intranasal use at 100–600 mcg per dose (mirroring the Semax convention but often at the lower end on the assumption of greater BBB penetration per microgram). Subcutaneous research-chemical protocols, where used, sit in roughly the same dose range. Any specific number reflects extrapolation from Semax convention, not data on Adamax itself.
Frequency
Once or twice daily during a course is the typical reported cadence, with intranasal users often dosing in the morning or before cognitively demanding work.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Forum protocols commonly describe 10–14 day on / 10–14 day off cycles, mirroring the Semax convention from Russian clinical use. Some users run shorter 7-day pulses or longer continuous courses; none of these durations is anchored in clinical evidence specific to Adamax.
Protocol Notes
Adamax is essentially a research-chemical-only compound. There is no clinician-facing protocol, no commercial pharmaceutical product, and no published pharmacokinetic data — even for Semax, the human PK literature is thin, and for Adamax it is absent. The intranasal route is preferred by convention because Semax-class peptides are positioned around nose-to-brain delivery, but adamantane-modified peptides have not been comparatively studied across intranasal versus subcutaneous administration. Research-chemical supply quality is a real consideration: adamantane conjugation chemistry is not trivial to perform reliably at small scale, and the actual structural identity and purity of vials sold as 'Adamax' has not been independently audited. Inferring effects from Semax's clinical literature to a structurally modified derivative produced by gray-market suppliers requires significant assumptions about identity, purity, and pharmacology, none of which are validated.
Adamax is not FDA-approved for any indication and has zero published clinical data. Cognitive enhancement and neuroprotection claims significantly exceed the available evidence base. It should not be used as a substitute for evaluation of cognitive complaints, ADHD, post-stroke recovery, or any neurological condition by a qualified clinician.
Timeline of Effects
Onset
No characterized onset profile from controlled work. Subjective user reports for intranasal Adamax describe cognitive effects (alertness, focus, verbal fluency) emerging within 30–60 minutes of administration, which mirrors the reported acute effects of Semax. Whether the structural modifications meaningfully alter onset timing has not been studied.
Peak Effect
Subjectively, peak acute cognitive effect is described in the 1–3 hour window after a dose, consistent with Semax. Cumulative effects over a multi-day course are reported by some users but are entirely anecdotal; no objective neuropsychological time-course data exists for Adamax.
After Discontinuation
No documented withdrawal or rebound. The adamantane modification is theorized to extend tissue residence relative to Semax, but in the absence of pharmacokinetic measurement this is supposition. Subjective effects fade within hours to days of cessation in user reports.
Common Questions
Who Adamax Is NOT For
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data; CNS-active modified peptides should not be given to developing brains without formal study.
- •History of seizure disorder — neuroactive peptides with melanocortin and BDNF/TrkB activity have unstudied seizure-threshold effects, and the adamantane component in this class can in principle interact with NMDA-related signaling.
- •Active psychiatric medication regimens (SSRIs, SNRIs, antipsychotics, lithium) — interactions with monoaminergic and BDNF-related modulation are unstudied and could be clinically meaningful.
- •Known hypersensitivity to peptide preparations or to research-chemical formulation excipients; nasal mucosal irritation history is also a relative contraindication for intranasal use.
Drug & Supplement Interactions
There are no documented clinical drug interactions for Adamax because no human pharmacovigilance studies exist. What follows is theoretical, drawn from the parent compound and the adamantane-class chemistry. The most plausible mechanistic concerns are with monoaminergic psychiatric medications (SSRIs, SNRIs, MAOIs, stimulant ADHD medications, antipsychotics) given Semax-class effects on dopamine, norepinephrine, and serotonin signaling — additive or opposing effects on neurotransmitter tone are unstudied. A second concern derives from the adamantane moiety: established adamantane derivatives (amantadine, memantine) have known dopaminergic and NMDA-antagonist effects respectively, and even if the adamantane group on Adamax is conjugated rather than free, novel CNS interactions cannot be ruled out without formal study. BDNF/TrkB modulation theoretically interacts with antiseizure medications, antidepressants with neurotrophic claims, and any agent affecting neuroplasticity. CYP-mediated pharmacokinetic interactions are not described and at the small doses involved are unlikely. Patients on any psychiatric or neurologic medication should disclose Adamax use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Zero published safety or efficacy data specific to Adamax
- • Not FDA-approved and not in clinical trials
- • Quality and purity from research peptide vendors is unverified
- • Extrapolating safety from Semax to a structurally modified derivative is uncertain
What We Don't Know
Everything about Adamax is unknown in a formal sense. No human or animal studies have been published. The compound's safety profile is entirely extrapolated from Semax research and general adamantane pharmacology. Whether the adamantane modification introduces new risks is unstudied.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient and not on the FDA's compounding-eligible peptide list. Available essentially only through research-chemical suppliers labeled 'not for human use.'
International
Not approved as a medicine in any Western regulatory jurisdiction. Unlike Semax, which holds Russian medicine registration for stroke and cognitive indications, Adamax does not have equivalent Russian regulatory status — it is a research-chemical derivative rather than a registered Russian pharmaceutical. Not authorized as a medicine by EMA, MHRA, TGA, or Health Canada.
Sports & Competition
Not specifically named on the WADA Prohibited List. Because no governmental regulatory health authority approves Adamax for human therapeutic use, it can reasonably be read as falling under WADA's S0 catch-all category. Athletes subject to WADA code should treat it as prohibited, particularly in injectable form.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Adamax is a more potent, evidence-based version of Semax.
Reality
It is more structurally modified than Semax, but 'more modified' is not 'more evidence-based.' Adamax has zero published clinical data; Semax has moderate clinical evidence from Russian use. Any potency claim is extrapolation from parent-compound work plus adamantane-class theory, not direct measurement.
Myth
The adamantane modification makes Adamax cross the blood-brain barrier far better than Semax.
Reality
The pharmacokinetic logic is reasonable in principle — adamantane-class chemistry is used in small-molecule CNS drugs precisely for lipophilicity and BBB penetration. But this has not been measured for Adamax. Theoretical superiority is not the same as demonstrated superiority.
Myth
Because Semax is approved as a medicine in Russia, Adamax inherits regulatory legitimacy.
Reality
Semax holds Russian medicine registration; Adamax does not. They are different chemical entities, and Russian regulatory approval of one does not transfer to the other. Adamax is a research-chemical derivative, full stop.
Myth
Research-chemical Adamax is reliably what the label says it is.
Reality
Adamantane conjugation chemistry is not trivial to perform consistently at small scale, and there is no independent quality auditing of gray-market vials sold as Adamax. The compound's identity, purity, and even whether the labeled adamantane group is correctly conjugated are assumptions, not verified facts.
Published Research
3 studiesSemax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.
Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke
Quick Facts
- Class
- Nootropic Peptide
- Tier
- F
- Evidence
- Limited
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 3PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.